Cargando…
FGFR1 fusion kinase regulation of MYC expression drives development of stem cell leukemia/lymphoma syndrome
Oncogenic transformation of hematopoietic stem cells by chimeric fusion kinases causing constitutive activation of FGFR1 leads to a stem cell leukemia/lymphoma (SCLL) syndrome, accompanied by widespread dysregulation of gene activity. We now show that FGFR1 activation is associated with upregulation...
Autores principales: | Hu, Tianxiang, Wu, Qing, Chong, Yating, Qin, Haiyan, Poole, Candace J., van Riggelen, Jan, Ren, Mingqiang, Cowell, John K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6168426/ https://www.ncbi.nlm.nih.gov/pubmed/29720732 http://dx.doi.org/10.1038/s41375-018-0124-y |
Ejemplares similares
-
Downregulation of PUMA underlies resistance to FGFR1 inhibitors in the stem cell leukemia/lymphoma syndrome
por: Liu, Yun, et al.
Publicado: (2020) -
The miR-17/92 cluster is involved in the molecular etiology of the SCLL syndrome driven by the BCR-FGFR1 chimeric kinase
por: Hu, Tianxiang, et al.
Publicado: (2018) -
Mechanisms of resistance to FGFR1 inhibitors in FGFR1-driven leukemias and lymphomas: implications for optimized treatment
por: Cowell, John K., et al.
Publicado: (2021) -
MYC—Master Regulator of the Cancer Epigenome and Transcriptome
por: Poole, Candace J., et al.
Publicado: (2017) -
Targeting the MYC Oncogene in Burkitt Lymphoma through HSP90 Inhibition
por: Poole, Candace J., et al.
Publicado: (2018)